KRAS and colorectal carcinoma: The inhibition of ERK activity, as well as GTP-RAS activity, by treatment with cetuximab or KYA1797K alone or in combination in CRC cells with different KRAS mutations was correlated with cell growth and transformation (Fig. 3e and Supplementary Figure S4c).